Related Experiment Video
Updated: May 18, 2026
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
100% human monoclonal antibodies in oncology: hype or breakthrough?
Stephan Benay1, Raphaelle Fanciullino, Cedric Mercier
1Laboratoire de Pharmacocinetique - UFR Pharmacie, 27 Bd Jean Moulin, 13385 Marseille, France.
Abstract:
Targeted therapies have dramatically modified treatment strategies in oncology since the early 2000's, especially for treating digestive cancers. These new biotherapies such as anti-VEGF (bevacizumab) or anti-EGFR (cetuximab) monoclonal antibodies have given oncologists new opportunities to use innovative treatment schedules or combinations with cytotoxics. Consequently, significant improvements in response rates, with trends to longer progression-free survival and/or overall survival have been achieved in patients with metastatic colorectal cancer (mCRC). Panitumumab is a novel, 100% human, anti-EGFR1 (HER1) antibody that has been approved in late 2007 for use as monotherapy in mCRC patients resistant to standard chemotherapy, provided that their tumor express EGFR and display wild-type K-Ras status. Panitumumab has been recently further approved in combination with chemotherapy in mCRC patients. However, owing to the fact that its mechanism of action for targeting EGFR is similar to that of chimeric cetuximab, picturing the specificities in pharmacological and pharmacokinetic properties of this 100% human antibody could help the oncologists to better define their strategies at the bedside.
Insights
Targeted therapies, including panitumumab, offer new options for metastatic colorectal cancer (mCRC). Understanding the specific properties of this fully human antibody can optimize treatment strategies for better patient outcomes.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Targeted therapies have transformed oncology, particularly for digestive cancers.
- Biotherapies like anti-VEGF and anti-EGFR monoclonal antibodies have improved treatment outcomes in metastatic colorectal cancer (mCRC).
Purpose of the Study:
- To review the pharmacological and pharmacokinetic properties of panitumumab, a fully human anti-EGFR antibody.
- To highlight the specificities of panitumumab compared to other anti-EGFR antibodies like cetuximab.
- To aid oncologists in optimizing treatment strategies for mCRC patients.
Main Methods:
- Review of pharmacological and pharmacokinetic data for panitumumab.
- Comparison of panitumumab's properties with chimeric anti-EGFR antibodies.
- Analysis of clinical data regarding panitumumab's efficacy and safety.
Main Results:
- Panitumumab is a fully human anti-EGFR antibody approved for mCRC patients resistant to chemotherapy, with EGFR-expressing and wild-type K-Ras tumors.
- It is also approved in combination with chemotherapy.
- Understanding its unique properties is crucial for clinical application.
Conclusions:
- Panitumumab offers a valuable therapeutic option for mCRC.
- Specific pharmacological and pharmacokinetic details of panitumumab are essential for effective clinical decision-making.
- Further understanding can refine treatment strategies for mCRC.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...